Preclinical and clinical studies of unrelieved aural fullness following intratympanic gentamicin injection in patients with intractable Ménière's disease

Feng Zhai, Ru Zhang, Ting Zhang, Peter Steyger, Chun Fu Dai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To clarify whether gentamicin affects vestibular dark cells in guinea pigs and relieves patients of aural fullness with intractable Ménière's disease following intratympanic administration. Materials and Methods: Purified gentamicin-Texas Red (GTTR) was injected intratympanically in guinea pigs that were sacrificed at 1, 3, 7, 14 and 28 days. GTTR uptake was examined in hair cells, and transitional cells and dark cells in vestibular end-organs were examined. Specific attention was paid to its distribution in dark cells under confocal microscopy, and the ultrastructure of dark cells using electron microscopy, following intratympanic injection. Results: Dark cells in the semicircular canals showed weak GTTR uptake at 1, 3, 7, 14 and 28 days after intratympanic injection, with no significant differences at various time points after injection. However, the adjacent transitional cells demonstrated intense GTTR uptake that was retained for at least 28 days. Ultrastructural studies demonstrated negligible characteristics associated with apoptosis or necrosis in these dark cells. The tight junctions between dark cells showed no signs of disruption at 7 or 28 days after injection. Conclusion: Intratympanic gentamicin has little direct impact on vestibular dark cells. Clinical Application: A modified low-dose titration intratympanic approach was used in 29 patients with intractable vertigo and the clinical outcomes were followed. Aural fullness following intratympanic gentamicin injection was not relieved based on our subjective scales, demonstrated by no statistically significant difference between preinjection (4.16 ± 3.08) and postinjection (3.58 ± 2.93; p > 0.05) aural fullness scores. Vertigo control was achieved in 88% of patients, with hearing deterioration identified in 16% of patients. Intratympanic gentamicin administration might not lead to relief of aural fullness in patients with intractable vertigo, although it can achieve a high vertigo control rate with some cochleotoxicity.

Original languageEnglish (US)
Pages (from-to)297-306
Number of pages10
JournalAudiology and Neurotology
Volume18
Issue number5
DOIs
StatePublished - 2013

Fingerprint

Gentamicins
Ear
Vertigo
Guinea Pigs
Intratympanic Injection
Clinical Studies
Semicircular Canals
Injections
Tight Junctions
Confocal Microscopy
Hearing
Electron Microscopy
Necrosis
Apoptosis
Texas red

Keywords

  • Aural fullness
  • Dark cells
  • Gentamicin
  • Intratympanic injection
  • Ménière's disease

ASJC Scopus subject areas

  • Physiology
  • Otorhinolaryngology
  • Sensory Systems
  • Speech and Hearing
  • Medicine(all)

Cite this

Preclinical and clinical studies of unrelieved aural fullness following intratympanic gentamicin injection in patients with intractable Ménière's disease. / Zhai, Feng; Zhang, Ru; Zhang, Ting; Steyger, Peter; Dai, Chun Fu.

In: Audiology and Neurotology, Vol. 18, No. 5, 2013, p. 297-306.

Research output: Contribution to journalArticle

@article{e370135175ef4696a011f82ae3799d38,
title = "Preclinical and clinical studies of unrelieved aural fullness following intratympanic gentamicin injection in patients with intractable M{\'e}ni{\`e}re's disease",
abstract = "Objective: To clarify whether gentamicin affects vestibular dark cells in guinea pigs and relieves patients of aural fullness with intractable M{\'e}ni{\`e}re's disease following intratympanic administration. Materials and Methods: Purified gentamicin-Texas Red (GTTR) was injected intratympanically in guinea pigs that were sacrificed at 1, 3, 7, 14 and 28 days. GTTR uptake was examined in hair cells, and transitional cells and dark cells in vestibular end-organs were examined. Specific attention was paid to its distribution in dark cells under confocal microscopy, and the ultrastructure of dark cells using electron microscopy, following intratympanic injection. Results: Dark cells in the semicircular canals showed weak GTTR uptake at 1, 3, 7, 14 and 28 days after intratympanic injection, with no significant differences at various time points after injection. However, the adjacent transitional cells demonstrated intense GTTR uptake that was retained for at least 28 days. Ultrastructural studies demonstrated negligible characteristics associated with apoptosis or necrosis in these dark cells. The tight junctions between dark cells showed no signs of disruption at 7 or 28 days after injection. Conclusion: Intratympanic gentamicin has little direct impact on vestibular dark cells. Clinical Application: A modified low-dose titration intratympanic approach was used in 29 patients with intractable vertigo and the clinical outcomes were followed. Aural fullness following intratympanic gentamicin injection was not relieved based on our subjective scales, demonstrated by no statistically significant difference between preinjection (4.16 ± 3.08) and postinjection (3.58 ± 2.93; p > 0.05) aural fullness scores. Vertigo control was achieved in 88{\%} of patients, with hearing deterioration identified in 16{\%} of patients. Intratympanic gentamicin administration might not lead to relief of aural fullness in patients with intractable vertigo, although it can achieve a high vertigo control rate with some cochleotoxicity.",
keywords = "Aural fullness, Dark cells, Gentamicin, Intratympanic injection, M{\'e}ni{\`e}re's disease",
author = "Feng Zhai and Ru Zhang and Ting Zhang and Peter Steyger and Dai, {Chun Fu}",
year = "2013",
doi = "10.1159/000351805",
language = "English (US)",
volume = "18",
pages = "297--306",
journal = "Audiology and Neurotology",
issn = "1420-3030",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Preclinical and clinical studies of unrelieved aural fullness following intratympanic gentamicin injection in patients with intractable Ménière's disease

AU - Zhai, Feng

AU - Zhang, Ru

AU - Zhang, Ting

AU - Steyger, Peter

AU - Dai, Chun Fu

PY - 2013

Y1 - 2013

N2 - Objective: To clarify whether gentamicin affects vestibular dark cells in guinea pigs and relieves patients of aural fullness with intractable Ménière's disease following intratympanic administration. Materials and Methods: Purified gentamicin-Texas Red (GTTR) was injected intratympanically in guinea pigs that were sacrificed at 1, 3, 7, 14 and 28 days. GTTR uptake was examined in hair cells, and transitional cells and dark cells in vestibular end-organs were examined. Specific attention was paid to its distribution in dark cells under confocal microscopy, and the ultrastructure of dark cells using electron microscopy, following intratympanic injection. Results: Dark cells in the semicircular canals showed weak GTTR uptake at 1, 3, 7, 14 and 28 days after intratympanic injection, with no significant differences at various time points after injection. However, the adjacent transitional cells demonstrated intense GTTR uptake that was retained for at least 28 days. Ultrastructural studies demonstrated negligible characteristics associated with apoptosis or necrosis in these dark cells. The tight junctions between dark cells showed no signs of disruption at 7 or 28 days after injection. Conclusion: Intratympanic gentamicin has little direct impact on vestibular dark cells. Clinical Application: A modified low-dose titration intratympanic approach was used in 29 patients with intractable vertigo and the clinical outcomes were followed. Aural fullness following intratympanic gentamicin injection was not relieved based on our subjective scales, demonstrated by no statistically significant difference between preinjection (4.16 ± 3.08) and postinjection (3.58 ± 2.93; p > 0.05) aural fullness scores. Vertigo control was achieved in 88% of patients, with hearing deterioration identified in 16% of patients. Intratympanic gentamicin administration might not lead to relief of aural fullness in patients with intractable vertigo, although it can achieve a high vertigo control rate with some cochleotoxicity.

AB - Objective: To clarify whether gentamicin affects vestibular dark cells in guinea pigs and relieves patients of aural fullness with intractable Ménière's disease following intratympanic administration. Materials and Methods: Purified gentamicin-Texas Red (GTTR) was injected intratympanically in guinea pigs that were sacrificed at 1, 3, 7, 14 and 28 days. GTTR uptake was examined in hair cells, and transitional cells and dark cells in vestibular end-organs were examined. Specific attention was paid to its distribution in dark cells under confocal microscopy, and the ultrastructure of dark cells using electron microscopy, following intratympanic injection. Results: Dark cells in the semicircular canals showed weak GTTR uptake at 1, 3, 7, 14 and 28 days after intratympanic injection, with no significant differences at various time points after injection. However, the adjacent transitional cells demonstrated intense GTTR uptake that was retained for at least 28 days. Ultrastructural studies demonstrated negligible characteristics associated with apoptosis or necrosis in these dark cells. The tight junctions between dark cells showed no signs of disruption at 7 or 28 days after injection. Conclusion: Intratympanic gentamicin has little direct impact on vestibular dark cells. Clinical Application: A modified low-dose titration intratympanic approach was used in 29 patients with intractable vertigo and the clinical outcomes were followed. Aural fullness following intratympanic gentamicin injection was not relieved based on our subjective scales, demonstrated by no statistically significant difference between preinjection (4.16 ± 3.08) and postinjection (3.58 ± 2.93; p > 0.05) aural fullness scores. Vertigo control was achieved in 88% of patients, with hearing deterioration identified in 16% of patients. Intratympanic gentamicin administration might not lead to relief of aural fullness in patients with intractable vertigo, although it can achieve a high vertigo control rate with some cochleotoxicity.

KW - Aural fullness

KW - Dark cells

KW - Gentamicin

KW - Intratympanic injection

KW - Ménière's disease

UR - http://www.scopus.com/inward/record.url?scp=84888234753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888234753&partnerID=8YFLogxK

U2 - 10.1159/000351805

DO - 10.1159/000351805

M3 - Article

C2 - 24008307

AN - SCOPUS:84888234753

VL - 18

SP - 297

EP - 306

JO - Audiology and Neurotology

JF - Audiology and Neurotology

SN - 1420-3030

IS - 5

ER -